 SAN DIEGO, Dec. 15, 2020 PRNewswire -- BioAtla, Inc. Nasdaq: BCAB, a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the pricing of its initial... 